Yellow capsules resting on the palm of a human being

Generic Drug Production

By Alexander Grey on Unsplash

Generic Drug Production

Country
Sector
Most major industry classification systems use sources of revenue as their basis for classifying companies into specific sectors, subsectors and industries. In order to group like companies based on their sustainability-related risks and opportunities, SASB created the Sustainable Industry Classification System® (SICS®) and the classification of sectors, subsectors and industries in the SDG Investor Platform is based on SICS.
Health Care
Sub Sector
Most major industry classification systems use sources of revenue as their basis for classifying companies into specific sectors, subsectors and industries. In order to group like companies based on their sustainability-related risks and opportunities, SASB created the Sustainable Industry Classification System® (SICS®) and the classification of sectors, subsectors and industries in the SDG Investor Platform is based on SICS.
Biotechnology and Pharmaceuticals
Indicative Return
Describes the rate of growth an investment is expected to generate within the IOA. The indicative return is identified for the IOA by establishing its Internal Rate of Return (IRR), Return of Investment (ROI) or Gross Profit Margin (GPM).
10% - 15% (in GPM)
Investment Timeframe
Describes the time period in which the IOA will pay-back the invested resources. The estimate is based on asset expected lifetime as the IOA will start generating accumulated positive cash-flows.
Long Term (10+ years)
Market Size
Describes the value of potential addressable market of the IOA. The market size is identified for the IOA by establishing the value in USD, identifying the Compound Annual Growth Rate (CAGR) or providing a numeric unit critical to the IOA.
< USD 50 million
Average Ticket Size (USD)
Describes the USD amount for a typical investment required in the IOA.
> USD 10 million
Direct Impact
Describes the primary SDG(s) the IOA addresses.
Good health and well-being (SDG 3) Industry, Innovation and Infrastructure (SDG 9)
Indirect Impact
Describes the secondary SDG(s) the IOA addresses.
No Poverty (SDG 1) Gender Equality (SDG 5)

Business Model Description

Invest to boost Lao PDR's generic drug production by establishing manufacturing facilities with local partners to produce generic drugs for the domestic market. Illustrative examples of enterprises operating in this space are:

PDC 3 is a state-owned pharmaceutical factory in Lao PDR that produces and distributes high-quality pharmaceutical products to meet the healthcare needs of the people in the country. (14)

Sinopharm Group is a Chinese pharmaceutical company that has established a joint venture with the Lao government to build a pharmaceutical factory in the country. The factory will produce a range of generic drugs for the domestic market and is expected to be completed in 2022. (14)

Zuellig Pharma: Zuellig Pharma is a leading healthcare services provider in Asia that has established a presence in Lao PDR through its subsidiary Zuellig Pharma Laos. The company provides distribution and logistics services for pharmaceuticals, medical devices, and consumer health products in the country. (15)

Expected Impact

Developing local capacity for generic drug production in Lao PDR is expected to increase access to affordable medicines and reduce import dependency.

How is this information gathered?

Investment opportunities with potential to contribute to sustainable development are based on country-level SDG Investor Maps.

Disclaimer

UNDP, the Private Finance for the SDGs, and their affiliates (collectively “UNDP”) do not seek or solicit investment for programmes, projects, or opportunities described on this site (collectively “Programmes”) or any other Programmes, and nothing on this page should constitute a solicitation for investment. The actors listed on this site are not partners of UNDP, and their inclusion should not be construed as an endorsement or recommendation by UNDP for any relationship or investment.

The descriptions on this page are provided for informational purposes only. Only companies and enterprises that appear under the case study tab have been validated and vetted through UNDP programmes such as the Growth Stage Impact Ventures (GSIV), Business Call to Action (BCtA), or through other UN agencies. Even then, under no circumstances should their appearance on this website be construed as an endorsement for any relationship or investment. UNDP assumes no liability for investment losses directly or indirectly resulting from recommendations made, implied, or inferred by its research. Likewise, UNDP assumes no claim to investment gains directly or indirectly resulting from trading profits, investment management, or advisory fees obtained by following investment recommendations made, implied, or inferred by its research.

Investment involves risk, and all investments should be made with the supervision of a professional investment manager or advisor. The materials on the website are not an offer to sell or a solicitation of an offer to buy any investment, security, or commodity, nor shall any security be offered or sold to any person, in any jurisdiction in which such offer would be unlawful under the securities laws of such jurisdiction.

Read More

Country & Regions

Explore the country and target locations of the investment opportunity.
Country
Region
  • Lao PDR: Vientiane Capital
  • Lao PDR: Champasak Province
  • Lao PDR: Savannakhet Province
  • Lao PDR: Luang Prabang Province
  • Lao PDR: Oudomxay Province
Learn more

Sector Classification

Situate the investment opportunity within sustainability focused sector, subsector and industry classifications.
Sector

Health Care

Lao PDR is ranked 135th (out of 195) in the 2019 Global Health Security Index [1]. High maternal and child mortality rates, malnutrition, and communicable diseases [2] are significant challenges. To improve public health outcomes, Lao PDR needs to strengthen healthcare infrastructure, enhance access to quality healthcare services, and invest in capacity building for healthcare professionals [3].

Policy priority
Lao PDR's policy priorities focus on achieving universal healthcare, improving access and quality of services, strengthening healthcare infrastructure, capacity building for healthcare professionals, and expanding health insurance coverage [4]. Additionally, reducing maternal and child mortality rates, addressing communicable diseases, and promoting health literacy.

Gender inequalities and marginalization issues
Women in Lao PDR face disparities in accessing healthcare services. Maternal mortality remains high at 46 per thousand live births[5]. In the healthcare workforce, women make up 38.5% of physicians[5]. These gender gaps are amplified in rural areas, where cultural norms, limited health literacy, and inadequate infrastructure further hinder women’s access to healthcare[6].

Investment opportunities introduction
Lao PDR's healthcare sector presents opportunities in API manufacturing and healthcare retail. Growing demand for pharmaceuticals supports local production, while expanding healthcare retail increases access to essential medicines, particularly in underserved rural areas.

Key bottlenecks introduction
Shortage and maldistribution of health workers, inadequate infrastructure [7]. Health financing is characterized by low government spending, reliance on out-of-pocket expenditure, and dependency on external aid [8]. Efforts to achieve Universal Health Coverage for vulnerable groups face hurdles due to these bottlenecks and the country's diverse, rural population [9].

Sub Sector

Biotechnology and Pharmaceuticals

"Development Need
Lao PDR's biotechnology and pharmaceuticals subsector is in a nascent stage. The country grapples with a high burden of infectious diseases and a pharmaceutical market that is over 90% import-dependent. Investment in R&D is minimal, indicating a need for strengthening this subsector [10]. "

Policy Priority
Lao PDR's policy objectives align with the need to enhance this subsector. The vision for universal healthcare, improved service quality, and expanded health insurance coverage necessitates a robust pharmaceutical industry [10].

"Gender Inequalities
Gender disparities are evident in Lao PDR's healthcare sector, with women constituting only 38.5% of physicians. These disparities are more pronounced in rural areas, where cultural norms and limited health literacy exacerbate the challenges women face in accessing healthcare [11]. "

"Investment Opportunities
The biotechnology and pharmaceuticals subsector in Lao PDR presents promising investment opportunities. The country's growing demand for pharmaceuticals and the need to reduce import dependency provide a conducive environment for API manufacturing and healthcare retail [12] "

Key Bottlenecks
Lao PDR's healthcare infrastructure faces significant challenges. The sector's heavy reliance on imports, particularly for pharmaceuticals, and an evolving regulatory framework for pharmaceuticals and medical devices could hinder the growth of the biotechnology and pharmaceuticals subsector [13].

Industry

Biotechnology and Pharmaceuticals

Pipeline Opportunity

Discover the investment opportunity and its corresponding business model.
Investment Opportunity Area

Generic Drug Production

To reduce imports and meet rising demand for medicines
Business Model

Invest to boost Lao PDR's generic drug production by establishing manufacturing facilities with local partners to produce generic drugs for the domestic market. Illustrative examples of enterprises operating in this space are:

PDC 3 is a state-owned pharmaceutical factory in Lao PDR that produces and distributes high-quality pharmaceutical products to meet the healthcare needs of the people in the country. (14)

Sinopharm Group is a Chinese pharmaceutical company that has established a joint venture with the Lao government to build a pharmaceutical factory in the country. The factory will produce a range of generic drugs for the domestic market and is expected to be completed in 2022. (14)

Zuellig Pharma: Zuellig Pharma is a leading healthcare services provider in Asia that has established a presence in Lao PDR through its subsidiary Zuellig Pharma Laos. The company provides distribution and logistics services for pharmaceuticals, medical devices, and consumer health products in the country. (15)

Business Case

Learn about the investment opportunity’s business metrics and market risks.

Market Size and Environment

Market Size (USD)
Describes the value in USD of a potential addressable market of the IOA.

< USD 50 million

CAGR
Describes the historical or expected annual growth of revenues in the IOA market.

5% - 10%

Critical IOA Unit
Describes a complementary market sizing measure exemplifying the opportunities with the IOA.

30,546,773 USD of medications were imported in Lao in 2022.

The total value of production for medicine was $13 million in 2021.

Indicative Return

GPM
Describes an expected percentage of revenue (that is actual profit before adjusting for operating cost) from the IOA investment.

10% - 15%

Generic drug manufacturers had a 20% profit margin in FY 2016, declining to 12.8% in FY 2019.(18)

Investment Timeframe

Timeframe
Describes the time period in which the IOA will pay-back the invested resources. The estimate is based on asset expected lifetime as the IOA will start generating accumulated positive cash-flows.

Long Term (10+ years)

The high upfront capital expenditure required to establish pharmaceutical manufacturing in Lao PDR will contribute to long term returns.

Ticket Size

Average Ticket Size (USD)
Describes the USD amount for a typical investment required in the IOA.

> USD 10 million

Market Risks & Scale Obstacles

Capital - CapEx Intensive

The cost of drug research and development, manufacturing, and marketing is high. There is a significant requirement for investments in equipment, facilities, and personnel that makes it a costly venture. [21]

Market - Highly Regulated

Manufacturing of druges in Lao PDR is primarily overseen by the Food and Drug Department (FDD).To import or export pharmaceuticals, food, or chemical products in Laos, importers must obtain a license from the Food and Drug Control Import Division of the Food and Drug Department (FDD) of the Ministry of Public Health. (22)

Impact Case

Read about impact metrics and social and environmental risks of the investment opportunity.

Sustainable Development Need

23% of Lao PDR's population lives below the national poverty line. Investments in this IOA can address challenges in access to affordable healthcare in Lao PDR where many struggle due to high medical costs and where out of pocket expenditure on medicines is especially high. (23)

Inadequate waste management in rural Lao PDR, with only 10% access to basic services, exacerbates health risks, increasing the demand for effective medical interventions and medicines to manage health risks.

70% of the Lao PDR population lacks adequate healthcare access.(23)

Gender & Marginalisation

Only 13% of women give birth with a skilled birth attendant, and maternal mortality is high at 197 per 100,000 live births. Additionally, only 30% of women use modern contraception. (24)

Ethnic groups such as the Hmong and Khmu face language and cultural barriers when accessing healthcare, leading to inadequate treatment and lower health outcomes.(25)

Expected Development Outcome

Increased availability of affordable medicines will directly contribute to improved health outcomes across the population, especially for those living in poverty or remote areas.

The local production of medicines could play a critical role in addressing the increased demand for healthcare products resulting from health risks.

By localizing drug production, the initiative could reduce dependency on imported medicines, improving access to medicines.

Gender & Marginalisation

Improved distribution of generic medicines will increase adoption of modern contraception.

By implementing gender-sensitive policies, such as ensuring equal pay and promoting diversity and inclusion, investments in this IOA can promote an inclusive workforce in pharmaceutical industry, and improve the work environment for marginalised groups and empower them

Primary SDGs addressed

Good health and well-being (SDG 3)
3 - Good Health and Well-Being

3.8.1 Coverage of essential health services

Current Value

Only 48% of the population has access to essential health services, including immunization, maternal and child health, and treatment for infectious diseases. (26)

Target Value

The government aims to reduce the global maternal mortality ratio to less than 70 per 100,000 live births by 2030. (24)

Industry, Innovation and Infrastructure (SDG 9)
9 - Industry, Innovation and Infrastructure

9.2.1 Manufacturing value added as a proportion of GDP and per capita

Current Value

The manufacturing value added as a proportion of GDP in Lao PDR was 15.7% in 2020. (27)

Target Value

The government is actively promoting investment in pharmaceutical manufacturing to support UHC by 2025. (26)

Secondary SDGs addressed

No Poverty (SDG 1)
1 - No Poverty
Gender Equality (SDG 5)
5 - Gender Equality

Directly impacted stakeholders

People

Patients and healthcare providers in Lao PDR will benefit from increased access to affordable medicines, particularly those from marginalized communities.

Gender inequality and/or marginalization

Women will benefit from increased access to healthcare/hygiene products.

Planet

Reduced carbon emissions from decreased transportation of pharmaceutical products and proper disposal of expired medicines, reducing environmental impact.

Corporates

Local pharmaceutical manufacturers, distributors, retailers, and foreign pharmaceutical companies operating in the Lao PDR market will benefit from increased product demand.

Public sector

The Lao government, particularly the Ministry of Health, will benefit from increased capacity to provide affordable medicines to the population and reduced healthcare expenditures.

Indirectly impacted stakeholders

People

Indirectly impacted stakeholders include family members and caregivers of patients who can benefit from increased access to affordable medicines, especially women and girls who often bear the burden of caring for sick family members.

Gender inequality and/or marginalization

Better access to healthcare options will empower women through increased productivity.

Planet

Increased local production of generic drugs can reduce environmental impact by reducing carbon emissions associated with transportation and packaging waste.

Corporates

International pharmaceutical companies may be indirectly impacted by reduced demand for their products in the Lao PDR market.

Public sector

Healthcare providers and public health agencies may be indirectly impacted by improved access to affordable medicines, leading to better health outcomes and reduced healthcare costs.

Outcome Risks

There is a risk of increased import dependency on foreign pharmaceutical companies, which could lead to higher prices and reduced access to essential medicines.

There is a risk that some manufacturers may be unable to compete with established providers and may struggle to sustain their operations.

Insufficient investment in research and development leading to limited innovation and lack of access to new treatments.

Local production of generic drugs may be subject to reduced quality control standards, which could lead to substandard medicines being distributed, putting patients' health at risk.

Gender inequality and/or marginalization risk: Women and marginalized communities may face limited access to affordable medicines due to systemic barriers to healthcare and economic opportunities.

Impact Risks

Dependence on imported raw materials leading to increased import costs and supply chain disruptions.

Inadequate quality control leading to substandard or unsafe drugs.

Insufficient investment in research and development leading to limited innovation and lack of access to new treatments.

Overreliance on one industry leads to economic volatility and a lack of diversification.

Gender inequality and/or marginalization risk: Women and marginalized communities may face limited access to affordable medicines due to systemic barriers to healthcare and economic opportunities.

Impact Classification

C—Contribute to Solutions

What

Developing local capacity for generic drug production to address import dependency and meet demand for affordable medicines.

Who

The Lao PDR healthcare system, patients, drug manufacturers, pharmaceutical distributors, and the environment.

Risk

Unintended negative consequences, such as environmental degradation, gender inequality, and marginalization.

Contribution

Lao PDR faces a high dependency on imported medicines, with a growing demand for affordable options. Developing local capacity for generic drug production can address this need.

How Much

Lao PDR imported $30,246,773 USD of medicament in 2022. This IOA will reduce import dependency for medicenes.

Impact Thesis

Developing local capacity for generic drug production in Lao PDR is expected to increase access to affordable medicines and reduce import dependency.

Enabling Environment

Explore policy, regulatory and financial factors relevant for the investment opportunity.

Policy Environment

A Policy Snapshot of Health and Nutrition in Lao PDR - provides a snapshot of government health spending, maternal and child expenditure, health care workers, and the status of nutrition. (28)

Health Sector Reform Strategy and Framework till 2025 - provides a legal and action framework for implementing the Health Sector Reform Strategy with a policy and strategic planning matrix. (29)

Country Programme Document for Lao PDR (2022-2026) - outlines the UNDP's programmatic priorities and strategies for development in the country, including in the health sector. (30)

"Policy on Primary Health Care" - provides an approach to primary health care, its basic components, strategy, and responsibilities at each level. (31)

Public Financial Management in the Health Sector in Lao People's Democratic Republic: Service Delivery Challenges and Opportunities - discusses the challenges in financing the health sector and the low level of government investment. (32)

Lao PDR's Ninth National Socio-Economic Development Plan (NSEDP 2021-2025): Outcome 2: Improved quality of human resources to meet development, research capacity, science and technology needs, and create value-added production and services

Financial Environment

Financial incentives:Investment Promotion Law (2016) offers tax breaks and other incentives to attract foreign investment in targeted sectors, including health sector. (34)

Fiscal incentives: Health Sector Reform Strategy (2013-2025) promotes increased public financing, greater efficiency, and strengthened health insurance systems. (35)

Other incentives: Public-Private Partnership (PPP) Policy encourages private sector participation in infrastructure development, including the health sector, by sharing risks and costs. (36)

Regulatory Environment

Law on Drug and Medical products: This Law determines the principles, rules, and measures relating to the use, management, monitoring, and inspection of drugs and medical products with the aim of ensuring the supply of drugs and medical products of good quality, efficacy, safety with appropriate prices in order to prevent diseases and to provide treatment to all people for their good health, contributing to the national protection and development.

Imported medicine regulations: Regulations on importing medicines to Lao PDR (33)

Regulation on Food, Drug and Medical Product Advertisement Control: Regulations on advertising of food, drugs, and medical products (34)

Banned drug list: List of drugs in Lao PDR which are illegal to manufacture or sell.

Marketplace Participants

Discover examples of public and private stakeholders active in this investment opportunity that were identified through secondary research and consultations.

Government

The Ministry of Health and the Ministry of Industry and Commerce are among the key government agencies responsible for overseeing the sector.

Multilaterals

The World Health Organization (WHO) is a key multilateral actor in the pharmaceutical manufacturing space in Lao PDR.

Non-Profit

Non-profit organizations such as the Clinton Health Access Initiative and the Lao Friends Hospital for Children are among the actors that are directly relevant for the pharmaceutical manufacturing space in Lao PDR.

Public-Private Partnership

PDC3, Sinopharm, CBF Pharma.

Target Locations

See what country regions are most suitable for the investment opportunity. All references to Kosovo shall be understood to be in the context of the Security Council Resolution 1244 (1999)
country static map
urban

Lao PDR: Vientiane Capital

Established infrastructure and skilled workforce make it a suitable location for pharmaceutical manufacturing—home to key government agencies responsible for regulating the pharmaceutical sector. The investment could create jobs and improve access to quality medicines.
urban

Lao PDR: Champasak Province

Rural province with a large tourism industry and a need for improved access to quality medicines. Investment in pharmaceutical manufacturing could help address this issue while creating jobs and supporting the local supply chain.
urban

Lao PDR: Savannakhet Province

It is the largest province with a strategic location on the border with Vietnam. Savan-Seno Special Economic Zone has attracted investment in several industries. Investment in pharmaceutical manufacturing could create jobs and improve access to quality medicines.
urban

Lao PDR: Luang Prabang Province

Province with a large rural population and a need for improved access to quality medicines. Investment in pharmaceutical manufacturing could help address this issue while contributing to the local economy through job creation and supporting local supply chains.

Lao PDR: Oudomxay Province

Capital of Oudomxay province with a large rural population and a need for improved access to quality medicines. Investment in pharmaceutical manufacturing could help address this issue while creating jobs and supporting the local supply chain

References

See what sources were used to establish the investment opportunity’s data and find resources that could be consulted to explore more.